Intracellular antibodies and challenges facing their use as therapeutic agents

Trends in Molecular Medicine

Volumn 9, Issue 9, 2003, Pages 390-396

  Lobato, M Natividad ^a   Rabbitts, Terence H ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; CASPASE 3; CHEMOKINE RECEPTOR CCR5; COMPLEMENTARY RNA; CYCLIN E; CYCLIN T1; DISULFIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN GP 120; HUNTINGTIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOLIPOSOME; INTEGRASE; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA; PROTEASOME; PROTEIN P53; RAS PROTEIN; REV PROTEIN; RNA DIRECTED DNA POLYMERASE; TAU PROTEIN; TRANSACTIVATOR PROTEIN; UBIQUITIN; VIF PROTEIN;

ANTIGEN BINDING; APOPTOSIS; B LYMPHOCYTE; CELLULAR DISTRIBUTION; COMPLEMENTARITY DETERMINING REGION; DISULFIDE BOND; HUMAN; IMMUNE SYSTEM; LIPID BILAYER; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 0141681221     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(03)00163-1     Document Type: Review

References (61)

1. Biocca, S. et al. (1990) Expression and targeting of intracellular antibodies in mammalian cells. EMBO J. 9, 101-108
2. Bird, R.E. et al. (1988) Single-chain antigen-binding proteins. Science 242, 423-426
3. Huston, J.S. et al. (1988) Protein engineering of antibodybinding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 85, 5879-5883
4. Marasco, W.A. et al. (1993) Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. U. S. A. 90, 7889-7893
5. Worn, A. and Pluckthun, A. (2001) Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305, 989-1010
6. Worn, A. and Pluckthun, A. (1998) An intrinsically stable antibody ScFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett. 427, 357-361
7. Proba, K. et al. (1998) Antibody scFv fragments without disulfide bonds made by molecular evolution. J. Mol. Biol. 275, 245-253
8. Ramm, K. et al. (1999) Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J. Mol. Biol. 290, 535-546
9. H in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 37, 13120-13127
10. Tse, E. et al. (2002) Intracellular antibody capture technology: application to selection of single chain Fv recognising the BCR-ABL oncogenic protein. J. Mol. Biol. 317, 85-94
11. Visintin, M. et al. (2002) The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. 317, 73-83
12. Visintin, M. et al. (1999) Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc. Natl. Acad. Sci. U. S. A. 96, 11723-11728
13. Tanaka, T. and Rabbitts, T.H. (2003) Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J. 22, 1025-1035
14. Proba, K. et al. (1997) A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J. Mol. Biol. 265, 161-172
15. Ohage, E.C. et al. (1999) Intrabody construction and expression. II. A synthetic catalytic Fv fragment. J. Mol. Biol. 291, 1129-1134
16. Ohage, E. and Steipe, B. (1999) Intrabody construction and expression. I. The critical role of VL domain stability. J. Mol. Biol. 291, 1119-1128
17. Desiderio, A. et al. (2001) A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold. J. Mol. Biol. 310, 603-615
18. Cattaneo, A. and Biocca, S. (1999) The selection of intracellular antibodies. Trends Biotechnol. 17, 115-121
19. Bai, J. et al. (2003) Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J. Biol. Chem. 278, 1433-1442
20. Levy-Mintz, P. et al. (1996) Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J. Virol. 70, 8821-8832
21. Wu, Y. et al. (1996) Binding of intracellular anti-rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J. Virol. 70, 3290-3297
22. Goncalves, J. et al. (2002) Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J. Biol. Chem. 277, 32036-32045
23. Tse, E. and Rabbitts, T.H. (2000) Intracellular antibody-caspase mediated cell killing: a novel approach for application in cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 97, 12266-12271
24. Zhou, P. et al. (2000) Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol. Cell 6, 751-756
25. Marasco, W.A. et al. (1998) Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum. Gene Ther. 9, 1627-1642
26. Steinberger, P. et al. (2000) Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. U. S. A. 97, 805-810
27. Alvarez, R.D. et al. (2000) A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 6, 3081-3087
28. Arafat, W. et al. (2000) Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target. Cancer Gene Ther 7, 1250-1256
29. Arafat, W.O. et al. (2002) Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 9, 256-262
30. Deshane, J. et al. (1995) Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96, 2980-2989
31. Graus-Porta, D. et al. (1995) Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15, 1182-1191
32. Richardson, J.H. et al. (1995) Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the a subunit of the receptor. Proc. Natl. Acad. Sci. U. S. A. 92, 3137-3141
33. Richardson, J.H. et al. (1998) Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther. 5, 635-644
34. Strube, R.W. and Chen, S.Y. (2002) Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-Fc intrabodies. J. Immunol. Methods 263, 149-167
35. Hyland, S. et al. (2003) Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor. Oncogene 22, 1557-1567
36. Biocca, S. et al. (1993) Intracellular expression of anti-p21ras single chain Fv fragments inhibits meiotic maturation of Xenopus oocytes. Biochem. Biophys. Res. Commun. 197, 422-427
37. Cochet, O. et al. (1998) Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58, 1170-1176
38. Caron de Fromentel, C. et al. (1999) Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18, 551-557
39. Lecerf, J.M. et al. (2001) Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 98, 4764-4769
40. Mhashilkar, A.M. et al. (2002) Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther. 9, 307-319
41. Wadia, J.S. and Dowdy, S.F. (2002) Protein transduction technology. Curr. Opin. Biotechnol. 13, 52-56
42. Allen, T.M. (2002) Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-783
43. Nielsen, U.B. et al. (2002) Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta Mol. Cell Res. 1591, 109-118
44. Sapra, P. and Allen, T.M. (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62, 7190-7194
45. Wagner, R.W. and Flanagan, W.M. (1997) Antisense technology and prospects for therapy of viral infections and cancer. Mol. Med. Today 3, 31-38
46. Hannon, G.J. (2002) RNA interference. Nature 418, 244-251
47. Tuschl, T. (2002) Expanding small RNA interference. Nat. Biotechnol. 20, 446-448
48. Ullu, E. et al. (2002) RNA interference: advances and questions. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 65-70
49. Brummelkamp, T.R. et al. (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553
50. Tanaka, T. et al. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. J. Mol. Biol. (in press)
51. Mhashilkar, A.M. et al. (1999) Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Hum. Gene Ther. 10, 1453-1467
52. Mhashilkar, A.M. et al. (1995) Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain antibody. EMBO J. 14, 1542-1551
53. Maciejewski, J.P. et al. (1995) Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat. Med. 1, 667-673
54. Gargano, N. et al. (1996) Human recombinant antibody fragments neutralizing human immunodeficiency virus type 1 reverse transcriptase provide an experimental basis for the structural classification of the DNA polymerase family. J. Virol. 70, 7706-7712
55. Shaheen, F. et al. (1996) Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J. Virol. 70, 3392-3400
56. Duan, L. et al. (1995) Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments. Hum. Gene Ther. 6, 1561-1573
57. Biocca, S. et al. (1994) Intracellular immunization with cytosolic recombinant antibodies. Biotechnology 12, 396-399
58. Ward, E.S. et al. (2003) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341, 544-546
59. Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest, National Institutes of Health
60. Lefranc, M-P. and Lefranc, G. (2001) The Immunoglobulin Facts Book, Academic Press
61. Lefranc, M.P. (2002) IMGT, the international ImMunoGeneTics database: a high-quality information system for comparative immunogenetics and immunology. Dev. Comp. Immunol. 26, 697-705